6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
Commission File Number 1-15182
DR. REDDYS LABORATORIES LIMITED
(Translation of registrants name into English)
7-1-27, Ameerpet
Hyderabad, Andhra Pradesh 500 016, India
+91-40-23731946
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if
submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home
country exchange on which the registrants securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the
registrants security holders, and, if discussing a material event, has already been the subject of
a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant
is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes o No þ
If Yes is marked, indicate below the file number assigned to registrant in connection with
Rule 12g3-2(b): 82-___.
The contents of this Form 6-K are hereby incorporated
into the Registration Statement on Form F-3 (File No. 333-138608) Dr. Reddys Laboratories Limited filed
with the Securities Exchange Commission on November 13, 2006.
This Report on Form 6-K shall be incorporated by reference in the automatic shelf Registration
Statement on Form F-3 (File No. 333-138608) (the Shelf Registration Statement) of Dr. Reddys
Laboratories Limited (the Company) and made part thereof, including the preliminary prospectus
supplement to the prospectus dated November 13, 2006 (the Prospectus Supplement, and, together
with the Shelf Registration Statement, the Registration Statement), each filed on November 13,
2006 with the United States Securities and Exchange Commission.
Other Events
On November 13, 2006, the Company filed the Shelf Registration Statement and subsequently filed the
Prospectus Supplement with the United States Securities and Exchange Commission in connection with its
offering of American Depositary Shares (the Offering).
In connection with the Offering, the Company hereby supplements the information set forth in the
Registration Statement.
TABLE OF CONTENTS
DILUTION
At June 30, 2006, we had a
net tangible book value of Rs.156.75 per equity share or
U.S.$3.42 per ADS (based on the noon buying rate in the City of New York on June 30, 2006 for cable
transfers in Indian rupees as certified for customs purposes by the Federal Reserve Bank of New
York, which was Rs.45.87 per U.S.$1.00 and the ratio of one equity share to one ADS). Net tangible
book value represents the amount of our total assets less our total liabilities, divided by
153,404,506, the total number of our equity shares outstanding at June 30, 2006.
After giving effect to the sale by us of 13,500,000 ADSs offered by us in the offering
described in our preliminary prospectus supplement dated November 13, 2006 and assuming (1) an
offering price of U.S.$17.22 per ADS, the closing price per ADS as reported on the New York Stock
Exchange on November 9, 2006, and (2) that the
underwriters over-allotment option is not
exercised, our net tangible book value estimated at November 9, 2006 would have been approximately
Rs.207.96 per equity share, representing U.S.$4.53 per ADS. This represents an immediate increase in net
tangible book value of Rs.51.21 per equity share, or U.S.$1.11 per ADS to existing shareholders and
an immediate dilution in net tangible book value of Rs.581.92 per equity share, or U.S.$12.69 per
ADS to new investors purchasing equity shares in this offering. Dilution for this purpose
represents the difference between the price per equity share or ADS paid by these purchasers and
net tangible book value per ADS immediately after the completion of the offering.
The following table illustrates this dilution to new investors purchasing ADSs, in the
offering:
|
|
|
|
|
|
|
|
|
|
|
Equity Shares |
|
|
ADSs |
|
Assumed initial public offering price per ADS |
|
|
Rs.773.35 |
(2) |
|
|
U.S.$17.22 |
(3) |
Net tangible book value per ADS at June 30, 2006 |
|
|
156.75 |
|
|
|
3.42 |
(4) |
Increase in net tangible book value per equity
share or ADS attributable to new investors |
|
|
51.21 |
|
|
|
1.11 |
(4) |
Pro forma net tangible book value per equity
share or ADS after the offering |
|
|
207.96 |
|
|
|
4.53 |
(4) |
Dilution per equity share or ADS to new investors |
|
|
Rs.581.92 |
|
|
|
U.S.$12.69 |
(4) |
Percentage of dilution in net tangible book
value per equity share or ADS for new
investors(1) |
|
|
75.25 |
% |
|
|
|
|
|
|
|
(1) |
|
Percentage of dilution for new investors is calculated by dividing the dilution in net
tangible book value for new investors in Indian Rupees by the price of the offering in Indian
Rupees. |
|
(2) |
|
Closing price per equity share as reported on the National
Stock Exchange of India Limited on November 9, 2006. |
|
(3) |
|
Closing price per ADS as reported on the New York Stock Exchange on November 9, 2006. |
|
(4) |
|
Translated for convenience only based on the noon buying rate in the City of New York on June
30, 2006, for cable transfers in Indian rupees as certified for customs purposes by the Federal
Reserve Bank of New York, which was Rs.45.87 per U.S.$1.00 and the ratio of one equity share to one
ADS. |
Each U.S.$1.00
increase (decrease) in the assumed offering price per equity share or per ADS,
respectively, would increase (decrease) the net tangible book value after this offering by Rs.3.71
per equity share or U.S.$0.08 per ADS assuming no exercise of the underwriters over-allotment
options and the dilution to investors in the offerings by Rs.42.16 per equity share or U.S.$0.92
per ADS, assuming that the number of ADSs offered in the offering, as set forth on the cover page
of the preliminary prospectus supplement filed on November 13, 2006, remains the same.
(2) CAPITALIZATION
The following tables set forth, as of September 30, 2006, our cash and capitalization
prepared in accordance with U.S. GAAP on:
|
|
|
an actual basis; and |
|
|
|
|
an adjusted basis giving effect to the sale by us of 13,500,000 ADSs offered by us in
the preliminary prospectus supplement filed on November 13, 2006, and assuming (1) an
offering price of U.S.$17.22 per ADS, the closing price per ADS as reported on the New York
Stock Exchange on November 9, 2006 and (2) that the underwriters over-allotment option
is not exercised. |
The following table should be read in conjunction with our consolidated financial statements
and the related notes and Managements Discussion and Analysis of Financial Condition and Results
of Operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2006 |
|
|
|
Actual |
|
|
As
adjusted for this offering |
|
|
|
(All amounts in thousand) |
|
|
|
Rs. |
|
|
U.S.$(1) |
|
|
Rs. |
|
|
U.S.$(1) |
|
Cash and
cash
equivalents(2) |
|
|
4,875,531 |
|
|
$ |
106,105 |
|
|
|
15,557,528 |
|
|
$ |
338,575 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings from banks |
|
|
8,817,947 |
|
|
|
191,903 |
|
|
|
8,817,947 |
|
|
|
191,903 |
|
Current portion of long term debt |
|
|
2,935,199 |
|
|
|
63,878 |
|
|
|
2,935,199 |
|
|
|
63,878 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total short term debt and current portion of long term debt |
|
|
11,753,146 |
|
|
|
255,781 |
|
|
|
11,753,146 |
|
|
|
255,781 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long term debt, excluding current portion |
|
|
20,607,472 |
|
|
|
448,476 |
|
|
|
20,607,472 |
|
|
|
448,476 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity shares at Rs.5 par value: 200,000,000 shares
authorized; Issued and outstanding: 153,515,604 shares
actual, 167,015,604 shares as adjusted(2) |
|
|
767,578 |
|
|
|
16,705 |
|
|
|
835,078 |
|
|
|
18,174 |
|
Additional paid in capital(2) |
|
|
9,930,832 |
|
|
|
216,123 |
|
|
|
20,545,329 |
|
|
|
447,124 |
|
Equity options outstanding |
|
|
492,210 |
|
|
|
10,712 |
|
|
|
492,210 |
|
|
|
10,712 |
|
Retained earnings |
|
|
14,959,592 |
|
|
|
325,562 |
|
|
|
14,959,592 |
|
|
|
325,562 |
|
Equity shares held by a controlled trust: 82,800 shares |
|
|
(4,882 |
) |
|
|
(106 |
) |
|
|
(4,882 |
) |
|
|
(106 |
) |
Accumulated and other comprehensive income |
|
|
361,054 |
|
|
|
7,858 |
|
|
|
361,054 |
|
|
|
7,858 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity(2) |
|
|
26,506,384 |
|
|
|
576,853 |
|
|
|
37,188,381 |
|
|
|
809,323 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total capitalization(2) |
|
|
58,867,002 |
|
|
|
1,281,110 |
|
|
|
69,548,999 |
|
|
|
1,513,580 |
|
(1) Translated for convenience only based on the noon buying rate in the City of New York on
September 30, 2006, for cable transfers in Indian rupees as certified for customs purposes by the
Federal Reserve Bank of New York, which was Rs.45.95 per U.S.$1.00 and the ratio of one equity
share to one ADS.
(2) Each
U.S.$1.00 increase (decrease) in the assumed offering price per ADS
would increase (decrease) each of cash and cash equivalents,
additional paid in capital, total stockholders equity and total
capitalization by Rs.620.3 million or U.S.$13.5 million, assuming
that the number of ADSs offered in the offering, as set forth on the
cover page of the preliminary prospectus supplement filed with the
Securities and Exchange Commission on November 13, 2006, remains the
same.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
DR. REDDYS LABORATORIES LIMITED
(Registrant)
|
|
Date: November 16, 2006 |
By: |
/s/ V Viswanath
|
|
|
|
Name: |
V Viswanath |
|
|
|
Title: |
Company Secretary |
|
|